Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Digestive System Neoplasms Clinical Trials

A listing of Digestive System Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (5) clinical trials

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Colorectal Non-small Cell Lung and Pancreatic Cancer

In a pre-clinical study, treatment of KRAS mutant (KRASm) colorectal cancer (CRC) cell lines with an inhibitor of multiple epidermal growth factor receptor (ErBb) kinases in combination with a MEK-inhibitor resulted in synthetic lethality. MEK inhibition alone in these cells resulted in a strong feedback activation of human epidermal growth ...

Phase

A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Advanced Cancer of the Stomach

IMU-131 is a single peptide structure composed of 3 individual B-cell epitope peptide sequences selected from HER2/neu structure. Polyclonal antibodies against IMU-131 peptides bind three separate regions of the HER2 receptor and also to the dimerization loop of the HER2 receptor, preventing dimerization, which in turn inhibits intracellular signaling. This ...

Phase

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Regorafenib (BAY 73-4506) was assessed in metastatic colorectal cancer in the phase III randomized CORRECT trial. 760 metastatic colorectal cancer patients were recruited after the failure of all standard therapies. Given the promising efficacy and favorable tolerability profile of mGEMOX and the potential benefits of targeting the VEGF and Ras/Raf ...

Phase

Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Arm A: Study Groups: If participant is found to be eligible to take part in this study, participant's doctor will decide which part of the study participant will be in based on the type of tumor participant has. The study doctor will discuss this with participant. Participant will be in ...

Phase